CRON CRON

Cronos Stock Price

3.13
0.06 (1.95%)
Upgrade to Real-Time
Afterhours (Closed)
3.13
Volume 494,526
Bid Price 3.09
Ask Price 3.14
News -
Day High 3.14

Low
2.57

52 Week Range

High
4.7395

Day Low 3.05
Company Name Stock Ticker Symbol Market Type
Cronos Group Inc CRON NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.06 1.95% 3.13 17:00:00
Open Price Low Price High Price Close Price Prev Close
3.06 3.05 3.14 3.13 3.07
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
2,590 494,526 $ 3.12 $ 1,540,923 - 2.57 - 4.7395
Last Trade Time Type Quantity Stock Price Currency
16:56:33 2 $ 3.09 USD

Period:

Draw Mode:

Cronos Group Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 1.18B 378.47M 200.05M $ 70.51M $ - - -5.30
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - -461.18k 5.00%

more financials information »

Cronos News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical CRON Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week3.093.2183.013.081,613,2000.041.29%
1 Month3.103.362.673.002,086,1060.030.97%
3 Months3.003.402.613.001,837,7010.134.33%
6 Months3.023.602.573.031,963,2340.113.64%
1 Year4.564.73952.573.412,156,955-1.43-31.36%
3 Years7.0915.832.576.733,941,117-3.96-55.85%
5 Years8.2425.09992.5710.325,788,153-5.11-62.01%

Cronos Description

Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S. multistate operator PharmaCann.